EANS-News: Epigenomics AG / Epigenomics signs licensing agreement with BioChain for Septin9 in China

--------------------------------------------------------------------------------
Corporate news transmitted by euro adhoc. The issuer/originator is solely
responsible for the content of this announcement.
--------------------------------------------------------------------------------

Licensing Agreements/New Products/Molecular Diagnostics

Berlin, Germany, Seattle, WA, and San Francisco, CA, U.S.A., Beijing,
China (euro adhoc) - Epigenomics AG (Frankfurt Prime Standard: ECX),
the German-American cancer molecular diagnostics company, and
BioChain, a leading Clinical Diagnostics company in cancer and
genetic tests, today announced that BioChain has licensed
Epigenomics' methylated Septin9 marker for the blood based detection
of colorectal cancer (CRC). BioChain, will offer a Septin9 assay as a
service to customers through its' Beijing based Chinese independent
reference laboratory.

Grace Tian, Chief Executive Officer of BioChain Institute, Inc.,
U.S.A., noted: "Through this agreement we will immediately initiate
efforts in China to validate and deploy the methylated Septin9 assay
allowing the establishment of new standards for access and
convenience in our home market. We see this effort as a first step in
developing a relationship with Epigenomics to bring early stage
cancer detection to the market."

Additionally, Dr. Thomas Taapken, Chief Financial Officer and acting
Chief Executive Officer of Epigenomics, commented: "We are pleased
that BioChain has decided to collaborate with us in making a
methylated Septin9 assay available in mainland China. This allows
more convenient alternatives for CRC screening to become available in
this emerging market, where prevalence of CRC in the population is on
the raise and growing awareness is creating a need for early
detection."

- Ends -

Contact Epigenomics AG

Antje Zeise
Manager IR | PR
Epigenomics AG
Tel +49 (0) 30 24345 368
ir@epigenomics.com
www.epigenomics.com

About BioChain

BioChain ({www.biochain.com}[HYPERLINK: http://www.biochain.com],
www.biochainbj.com) is a manufacturer of Life Sciences tools and the
pioneer of molecular genetics diagnostics in the US and China. It is
also the owner and operator of an independent reference laboratory,
equivalent of a CLIA lab, in China - Beijing BioChain Medical
Laboratory (BBML). BBML is unique in that it focuses on the
application of molecular diagnostics technologies and products. BBML
is located in the economic development zone of Beijing, China.
Through BBML, BioChain is committed to the application of the cutting
edge "omics" technologies in the areas of reproductive health and
cancer diagnosis.

BBML offers comprehensive services to its customers in China with a
list of cellular and molecular test menus based on diverse
technologies appropriate to each stage and type of disease.
Technology platforms employed by BioChain include karyotyping
analysis of cytogenetics, fluorescent in-situ hybridization (FISH),
array comparative genomic hybridization (aCGH), quantitative PCR
(qPCR), Sanger sequencing, next generation sequencing (NGS),
multiplex ligation-dependent probe amplification (MLPA), and genetic
linkage analysis. BioChain has a strong bioinformatics team and
established the first Chromosomal Health Database for the Chinese
population (www.szjkzd.org:8080/app/auth).

About Epigenomics

Epigenomics (www.epigenomics.com) is a molecular diagnostics company
developing and commercializing a pipeline of proprietary products for
cancer. The Company's products enable doctors to diagnose cancer
earlier and more accurately, leading to improved outcomes for
patients. Epigenomics' lead product, Epi proColon®, is a blood-based
test for the early detection of colorectal cancer, which is currently
marketed in Europe and is in development for the U.S.A. The Company's
technology and products have been validated through multiple
partnerships with leading global diagnostic companies including
Abbott, QIAGEN, Sysmex, and Quest Diagnostics. Epigenomics is an
international company with operations in Europe and the U.S.A.

Epigenomics legal disclaimer

This communication expressly or implicitly contains certain
forward-looking statements concerning Epigenomics AG and its
business. Such statements involve certain known and unknown risks,
uncertainties and other factors which could cause the actual results,
financial condition, performance or achievements of Epigenomics AG to
be materially different from any future results, performance or
achievements expressed or implied by such forward-looking statements.
Epigenomics AG is providing this communication as of this date and
does not undertake to update any forward-looking statements contained
herein as a result of new information, future events or otherwise.

The information contained in this communication does not constitute
nor imply an offer to sell or transfer any product, and no product
based on this technology is currently available for sale by
Epigenomics in the United States or Canada. The analytical and
clinical performance characteristics of any Epigenomics product based
on this technology which may be sold at some future time in the U.S.
have not been established.

Further inquiry note:
Antje Zeise | CIRO
Manager IR/PR
Epigenomics AG
Tel: +49 30 24345 386

end of announcement euro adhoc
--------------------------------------------------------------------------------

company: Epigenomics AG
Kleine Präsidentenstraße 1
D-10178 Berlin
phone: +49 30 24345-0
FAX: +49 30 24345-555
mail: ir@epigenomics.com
WWW: http://www.epigenomics.com
sector: Biotechnology
ISIN: DE000A1K0516
indexes: Prime All Share, Technology All Share
stockmarkets: free trade: Berlin, München, Hamburg, Düsseldorf, Stuttgart,
regulated dealing/prime standard: Frankfurt
language: English